-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Zenas BioPharma, Raises Price Target to $48

Benzinga·09/30/2026 20:37:03
Citigroup analyst Yigal Nochomovitz maintains Zenas BioPharma (NASDAQ:ZBIO) with a Buy and raises the price target from $41 to $48.